Immunogenicity and Safety of AS03-adjuvanted H5N1 Influenza Vaccine in Children 6-35 Months of Age: Results From a Phase 2, Randomized, Observer-blind, Multicenter, Dose-ranging Study.
Joon-Hyung KimMamadou DrameThanyawee PuthanakitNan-Chang ChiuKhuanchai SupparatpinyoLi-Min HuangCheng-Hsun ChiuPo-Yen ChenKao-Pin HwangJasur DanierDamien FrielBruno SalaunWayne WooDavid W VaughnBruce L InnisAnne E SchuindPublished in: The Pediatric infectious disease journal (2022)
All formulations were highly immunogenic and demonstrated acceptable safety profiles, with the 1.9 µg HA/AS03B providing the most favorable balance of immunogenicity versus reactogenicity for use in children 6-35 months of age.